[Response to an antiestrogen as a criterion for hormonal sensitivity of endometrial cancer].
A test is described for the evaluation of hormone sensitivity of endometrial cancer in vivo. The concentrations of progesterone and estradiol receptors, and the activities of ornithine-decarboxylase and 17 beta-hydroxysteroid oxido-reductase enzymes have been measured in the tumor, before and after administration of the anti-estrogen tamoxifen. The responses observed, in particular the increase of progesterone receptor, could allow a more rational approach to hormonal therapy of endometrial cancer.
D015067:17-Hydroxysteroid Dehydrogenases / Q000378:metabolism; D004958:Estradiol / Q000032:analysis; D005260:Female; D006801:Humans; D009955:Ornithine Decarboxylase / Q000378:metabolism; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D013256:Steroids / Q000032:analysis*; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000201:enzymology
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013256:Steroids; D013629:Tamoxifen; D004958:Estradiol; D015067:17-Hydroxysteroid Dehydrogenases; D009955:Ornithine Decarboxylase
Réponse à un anti-oestrogène comme critère d'hormono-sensibilité du cancer de l'endomètre.